Should be co-administered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailability.
Source: NLP:carbidopa
13 interactions on record
Should be co-administered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailability.
Source: NLP:carbidopa
Should be coadministered with caution; iron salts can form chelates with levodopa and carbidopa, reducing bioavailability.
Source: NLP:carbidopa and levodopa
May reduce efficacy of carbidopa, levodopa and entacapone tablets.
Source: NLP:carbidopa, levodopa and entacapone
Dexlansoprazole can reduce the absorption of iron salts due to its effect on gastric pH.
Source: NLP:dexlansoprazole
Esomeprazole can reduce iron salt absorption due to effects on gastric acid secretion.
Source: NLP:esomeprazole dr
Esomeprazole magnesium may interfere with iron salts bioavailability due to effects on gastric pH.
Source: NLP:esomeprazole magnesium
Esomeprazole magnesium may interfere with iron salts bioavailability due to effects on gastric pH.
Source: NLP:esomeprazole magnesium delayed release capsules
Lansoprazole can reduce absorption due to its effect on reducing intragastric acidity.
Source: NLP:lansoprazole
Omeprazole may interfere with iron salts absorption as gastric pH affects its bioavailability.
Source: NLP:omeprazole
Pantoprazole sodium can reduce absorption of iron salts due to its effect on reducing intragastric acidity.
Source: NLP:pantoprazole
Pantoprazole may decrease absorption of iron salts due to increased gastric pH.
Source: NLP:pantoprazole sodium
Pantoprazole reduces gastric pH which may decrease absorption of iron salts.
Source: NLP:pantoprazole sodium granules
May interfere with absorption of iron salts where gastric pH is important for bioavailability.
Source: NLP:rabeprazole sodium